BDSI - BioDelivery Sciences International, Inc.
| Previous Close | 2.20 |
| Open | 2.25 |
| Bid | 1.90 x 1000 |
| Ask | 2.30 x 1400 |
| Day's Range | 2.22 - 2.30 |
| 52 Week Range | 1.60 - 3.60 |
| Volume | 172,519 |
| Avg. Volume | 444,090 |
| Market Cap | 131.512M |
| Beta | 0.34 |
| PE Ratio (TTM) | 25.00 |
| EPS (TTM) | 0.09 |
| Earnings Date | May 14, 2018 - May 18, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.58 |
- GlobeNewswire•10 hours ago
Recent Analysis Shows J.Jill, BankUnited, Toronto Dominion Bank, Adamis Pharmaceuticals, BioDelivery Sciences International, and First Solar Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Zacks•4 days ago
Why Is BioDelivery Sciences (BDSI) Up 2.4% Since Its Last Earnings Report?
BioDelivery Sciences (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- American City Business Journals•16 days ago
From BDSI to Red Hat: The Triangle's top inside stock sales of 1Q2018
From BioDelivery Sciences International to Red Hat, insiders at Triangle companies raked in millions in the first three months of 2018, public records show.
- Zacks•29 days ago
BioDelivery Sciences (BDSI) in Focus: Stock Moves 5.1% Higher
Shares of BioDelivery Sciences (BDSI) rose over 5% yesterday.
- ACCESSWIRE•29 days ago
Blog Exposure - Dova Pharma Inked Agreement with Fosun Pharma for Distribution of Avatrombopag in Mainland China and Hong Kong
Stock Monitor: BioDelivery Sciences Intl. Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 21, 2018 / Active-Investors.com has just released a free research report on Dova Pharmaceuticals, Inc. ...
- Zacks•last month
BioDelivery (BDSI) Q4 Loss Wider-Than-Expected, Sales Up Y/Y
BioDelivery (BDSI) reports wider-than-expected loss in Q4. However, revenues surpass estimates and increase substantially year over year.
- Thomson Reuters StreetEvents•last month
Edited Transcript of BDSI earnings conference call or presentation 15-Mar-18 8:30pm GMT
Q4 2017 BioDelivery Sciences International Inc Earnings Call
- American City Business Journals•last month
Raleigh pharma quadruples revenue, lands new contract
BDSI reported net revenue of $62.0 million for 2017, compared to $15.5 million for the year prior. "2017 was an important year for BDSI and one of great change," said Scott Plesha, president of BDSI, on the company's quarterly and full-year financial results call Thursday afternoon.
- American City Business Journals•last month
Raleigh pharma quadruples revenue, lands new contract
Raleigh's BioDelivery Sciences International quadrupled revenue in 2017 and landed a new contract with Humana after reacquiring pain management drug Belbuca from Endo Pharmaceuticals at the beginning of last year.
- GlobeNewswire•last month
CORRECTING and REPLACING -- BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
In a release issued under the same headline earlier today by BioDelivery Sciences International, Inc., please note that in the second bullet of the Corporate section, the end date of the non-exclusive ...
- Associated Press•last month
BioDelivery reports 4Q loss
The Raleigh, North Carolina-based company said it had a loss of 29 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•last month
BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
Full-year 2017 net revenue of $62.0 million vs. $15.5 million in 2016. BELBUCA ® fourth quarter 2017 net revenue of $9.4 million vs. $6.4 million in third quarter; an increase of 47%. BELBUCA prescription ...
- ACCESSWIRE•last month
BioDelivery Sciences International, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018, at ...
- Simply Wall St.•last month
What You Must Know About BioDelivery Sciences International Inc’s (NASDAQ:BDSI) ROE
BioDelivery Sciences International Inc (NASDAQ:BDSI) delivered an ROE of 29.45% over the past 12 months, which is an impressive feat relative to its industry average of 10.88% during the sameRead More...
- GlobeNewswire•last month
BioDelivery Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference
RALEIGH, N.C., March 14, 2018-- BioDelivery Sciences International, Inc., a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that Scott Plesha, President ...
- GlobeNewswire•last month
BioDelivery Sciences to Host Conference Call and Webcast Reporting Fourth Quarter and Full-Year 2017 Financial Results on Thursday, March 15
RALEIGH, N.C., March 07, 2018-- BioDelivery Sciences International, Inc., a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that it will report ...
- GlobeNewswire•last month
BioDelivery Sciences to Present at the 30th Annual ROTH Conference
RALEIGH, N.C., March 05, 2018-- BioDelivery Sciences International, Inc., a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that Scott Plesha, President ...
- Zacks•2 months ago
What's in the Cards for BioDelivery (BDSI) in Q4 Earnings?
BioDelivery's (BDSI) lead drugs Belbuca and Bunavail look promising to deliver an earnings beat in Q4.
- Zacks•2 months ago
Endo (ENDP) Surpasses Earnings, Revenue Estimates in Q4
Endo International (ENDP)'s fourth quarter results surpassed expectations but were down year-over-year due to weakness in the generics business.
- American City Business Journals•2 months ago
United Therapeutics settles patent litigation over $157M drug
United Therapeutics has settled patent litigation over a $157 million drug. The company (UTHR) reached an agreement with Actavis Laboratories FL, which is a subsidiary of generic giant Teva Pharmaceuticals, that resolves litigation over certain patents related to one of United Therapeutics' pulmonary arterial hypertension drugs: Orenitram. The settlement agreement allows Actavis to begin manufacturing and commercializing a generic version of the drug in June 2027 or potentially earlier under some circumstances. However, United Therapeutics noted that the agreement doesn't allow Actavis to manufacture generic versions of other products like Tyvaso or Remodulin.
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind Great Lakes Dredge & Dock, American Midstream Partners, LP, BioDelivery Sciences International, Viking Therapeutics, Pattern Energy Group, and Computer Programs and Systems — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Feb. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Great ...
- American City Business Journals•2 months ago
BDSI reaches settlement with generic drug giant Teva
Raleigh-based BioDelivery Sciences International (Nasdaq: BDSI) has settled the last of its outstanding patent litigation filed against generic manufacturing giant Teva Pharmaceuticals . BDSI said Tuesday ...
- GlobeNewswire•2 months ago
BioDelivery Sciences Announces BELBUCA® Patent Litigation Settlement Agreement with Teva
RALEIGH, N.C., Feb. 06, 2018-- BioDelivery Sciences International, Inc. today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, ...
CNW Group•3 months agoBELBUCA® - A New Treatment Option for Canadians Living With Chronic Pain - Now Available in Canada
BELBUCA® - A New Treatment Option for Canadians Living With Chronic Pain - Now Available in Canada
- GlobeNewswire•3 months ago
BioDelivery Sciences Announces Launch and Availability of BELBUCA® in Canada
RALEIGH, N.C., Jan. 30, 2018--. BioDelivery Sciences International, Inc. and Purdue Pharma announced today that BELBUCA ® buccal film is now commercially available in Canada. The first commercial sale ...
